- ≥99% by HPLC per component; lot-matched COA
- Lot-matched certificate of analysis
- Ships next business day, tracked
Retatrutide + Cagrilintide
Co-formulated 15 mg vial pairing a triple incretin agonist with an amylin analogue
- FormLyophilized powder, sealed glass vial
- Research areasIncretin and amylin receptor signalling, energy balance, metabolic models
Supplied for laboratory research use only. Not for human or veterinary use, and not intended to diagnose, treat, cure or prevent any disease.
Overview
This co-formulated vial pairs two of the most actively researched metabolic peptides of the past decade. Retatrutide is a synthetic 39-residue analogue engineered to engage three receptors at once — GIP, GLP-1 and glucagon — and carries a lipidated side chain that extends its circulating half-life. Cagrilintide is a long-acting analogue of amylin, the pancreatic hormone co-secreted with insulin, and acts through amylin and calcitonin receptor populations.
MyPeptide supplies the blend as a lyophilized powder in a sealed glass vial, assayed to ≥99% purity per component by HPLC and released against a lot-matched certificate of analysis. Both components are large, structurally complex peptides, and the certificate reports each separately. The material is sold as a research chemical for laboratory investigation only and is not a drug, is not approved for any use in humans, and carries no dosing guidance.
Specifications
Supply & purity
- Form
- Lyophilized powder, sealed glass vial
- Purity
- ≥99% by HPLC per component; lot-matched COA
- Solubility
- Bacteriostatic water; add slowly and avoid agitation
Handling & storage
- Storage (lyophilized)
- −20 °C, protected from light and moisture
- Storage (reconstituted)
- 2–8 °C, protected from light
Additional detail
- Product type
- Two-peptide metabolic research blend, single vial
- Components
- Retatrutide (LY3437943) and cagrilintide (AM833)
- Total peptide content
- 15 mg per vial — retatrutide 12.5 mg, cagrilintide 2.5 mg
- Retatrutide
- CAS 2381089-83-2 · C221H342N46O68 · 4731.30 g/mol
- Cagrilintide
- CAS 1415456-99-3 · C194H309N55O59S2 · 4409.07 g/mol
- Retatrutide class
- GIP / GLP-1 / glucagon triple receptor agonist, 39 residues
- Cagrilintide class
- Long-acting amylin and calcitonin receptor agonist, 32 residues
- Research areas
- Incretin and amylin receptor signalling, energy balance, metabolic models
Questions about Retatrutide + Cagrilintide
What is the ratio in this vial?
Retatrutide 12.5 mg to cagrilintide 2.5 mg, a 5:1 split by mass across a 15 mg total. Because the two peptides have similar molecular weights, around 4,731 and 4,409 g/mol, the molar ratio is close to the mass ratio.
Why combine an incretin agonist with an amylin analogue?
They act through separate receptor families. Retatrutide engages GIP, GLP-1 and glucagon receptors; cagrilintide acts at amylin and calcitonin receptors. Research designs that want both signalling arms present in a single preparation use a co-formulation rather than two vials.
Is the certificate of analysis component-specific?
Yes. Because this is a blend, the lot-matched COA reports HPLC identity and purity for retatrutide and cagrilintide separately rather than as one combined figure. The current lot document can be requested before ordering.
Can the components be used at different ratios?
Not from this vial. A co-formulation fixes the ratio at 12.5 to 2.5 mg. Study designs that need to vary one peptide independently should use separate retatrutide and cagrilintide vials, which MyPeptide also stocks in several sizes.
Related
